UCB SA (UCB) - Total Assets

Latest as of December 2025: €18.16 Billion EUR ≈ $21.23 Billion USD

Based on the latest financial reports, UCB SA (UCB) holds total assets worth €18.16 Billion EUR (≈ $21.23 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check UCB cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.

UCB SA - Total Assets Trend (2000–2025)

This chart illustrates how UCB SA's total assets have evolved over time, based on quarterly financial data. Explore UCB SA long-term investment intensity to see how much of total assets are deployed in long-term investments.

UCB SA - Asset Composition Analysis

Current Asset Composition (December 2025)

UCB SA's total assets of €18.16 Billion consist of 33.3% current assets and 66.7% non-current assets.

Asset Category Amount (EUR) % of Total Assets
Cash & Equivalents €0.00 12.4%
Accounts Receivable €1.79 Billion 9.8%
Inventory €1.50 Billion 8.2%
Property, Plant & Equipment €0.00 0.0%
Intangible Assets €3.45 Billion 19.0%
Goodwill €5.09 Billion 28.0%

Asset Composition Trend (2000–2025)

This chart illustrates how UCB SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see UCB stock market capitalisation.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: UCB SA's current assets represent 33.3% of total assets in 2025, an increase from 0.0% in 2000.
  • Cash Position: Cash and equivalents constituted 12.4% of total assets in 2025, up from 4.7% in 2000.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 46.0% of total assets, an increase from 4.0% in 2000.
  • Asset Diversification: The largest asset category is goodwill at 28.0% of total assets.

UCB SA Competitors by Total Assets

Key competitors of UCB SA based on total assets are shown below.

Company Country Total Assets
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653
China CN¥7.21 Billion
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
USA $7.59 Billion
Bachem Holding AG
SW:BANB
Switzerland CHF2.11 Billion
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821
China CN¥20.70 Billion
ABL Bio Inc
KQ:298380
Korea ₩280.93 Billion
Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPP
USA $497.60 Million
Ascletis Pharma Inc
F:2VJ
Germany €2.07 Billion
ABCELLERA BIOLOGICS
F:8QQ
Germany €1.36 Billion

UCB SA - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 1.38 1.36 1.27
Quick Ratio 1.04 0.99 0.97
Cash Ratio 0.00 0.00 0.00
Working Capital €1.65 Billion €1.26 Billion €768.00 Million

UCB SA - Advanced Valuation Insights

This section examines the relationship between UCB SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 4.05
Latest Market Cap to Assets Ratio 2.45
Asset Growth Rate (YoY) 4.7%
Total Assets €18.16 Billion
Market Capitalization $44.56 Billion USD

Valuation Analysis

Premium Asset Valuation: The market values UCB SA's assets at a significant premium (2.45x), suggesting investors see substantial growth potential or unique competitive advantages.

Positive Asset Growth: UCB SA's assets grew by 4.7% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for UCB SA (2000–2025)

The table below shows the annual total assets of UCB SA from 2000 to 2025.

Year Total Assets Change
2025-12-31 €18.16 Billion
≈ $21.23 Billion
+4.68%
2024-12-31 €17.35 Billion
≈ $20.28 Billion
+11.64%
2023-12-31 €15.54 Billion
≈ $18.17 Billion
-2.07%
2022-12-31 €15.87 Billion
≈ $18.55 Billion
+11.67%
2021-12-31 €14.21 Billion
≈ $16.61 Billion
+6.69%
2020-12-31 €13.32 Billion
≈ $15.57 Billion
+20.20%
2019-12-31 €11.08 Billion
≈ $12.95 Billion
+5.39%
2018-12-31 €10.51 Billion
≈ $12.29 Billion
+6.02%
2017-12-31 €9.92 Billion
≈ $11.59 Billion
-2.89%
2016-12-31 €10.21 Billion
≈ $11.94 Billion
-6.79%
2015-12-31 €10.96 Billion
≈ $12.81 Billion
+7.96%
2014-12-31 €10.15 Billion
≈ $11.86 Billion
+3.98%
2013-12-31 €9.76 Billion
≈ $11.41 Billion
+4.27%
2012-12-31 €9.36 Billion
≈ $10.94 Billion
+1.98%
2011-12-31 €9.18 Billion
≈ $10.73 Billion
+2.33%
2010-12-31 €8.97 Billion
≈ $10.49 Billion
-1.66%
2009-12-31 €9.12 Billion
≈ $10.66 Billion
-4.24%
2008-12-31 €9.52 Billion
≈ $11.13 Billion
-0.32%
2007-12-31 €9.55 Billion
≈ $11.17 Billion
-8.98%
2006-12-31 €10.50 Billion
≈ $12.27 Billion
+122.56%
2005-12-31 €4.72 Billion
≈ $5.51 Billion
-12.22%
2004-12-31 €5.37 Billion
≈ $6.28 Billion
+73.85%
2003-12-31 €3.09 Billion
≈ $3.61 Billion
+17.93%
2002-12-31 €2.62 Billion
≈ $3.06 Billion
+2.23%
2001-12-31 €2.56 Billion
≈ $3.00 Billion
+11.32%
2000-12-31 €2.30 Billion
≈ $2.69 Billion
--

About UCB SA

BR:UCB Belgium Biotechnology
Market Cap
$56.06 Billion
€47.95 Billion EUR
Market Cap Rank
#607 Global
#3 in Belgium
Share Price
€251.90
Change (1 day)
+1.45%
52-Week Range
€155.15 - €285.40
All Time High
€285.40
About

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, … Read more